Nanexa’s business model is based on developing the company’s drug delivery platform PharmaShell®, as well as running product projects based on the company technology. Nanexa aims at out-licensing the right to use the technology in specified areas. These areas may be defined to specific drug substances or groups of substances, indications, and/or geographical areas.
The business model is based on receiving compensation in the form of “down payments”, payments at achievement of milestones and royalties on products sold. Nanexa out-licenses the PharmaShell® technology in itself for cases where a pharmaceutical company wishes to develop its own pharmaceutical product. An alternative is that Nanexa develops its own product candidate based on the PharmaShell® technology for out-licensing, together with a specific drug substance.